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THERAPEUTICS
Newer drugs for focal epilepsy in adults
Martin J Brodie professor 1, Patrick Kwan professor of neurology 2 consultant neurologist 3
1Epilepsy Unit, Western Infirmary, Glasgow G11 6NT, UK; 2Departments of Medicine and Neurology, University of Melbourne, Royal Melbourne
Hospital, Melbourne VIC 3050, Australia; 3Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong
This is one of a series of occasional articles on therapeutics for common
or serious conditions, covering new drugs and old drugs with important
new indications or concerns. The series advisers are Robin Ferner,
honorary professor of clinical pharmacology, University of Birmingham
and BirminghamCity Hospital, and Philip Routledge, professor of clinical
pharmacology, Cardiff University. To suggest a topic for this series,
please email us at practice@bmj.com.
A 28 year old woman sees her general practitioner after
experiencingwhat sounds like a convulsionwithout any apparent
provoking factor. Over the past month she has also had “blank
spells” during which her husband noticed her to be unresponsive.
Her general practitioner suspects she may have developed focal
epilepsy and refers her to an epilepsy specialist. The specialist
elicits from the patient and her husband additional features in
the history that are highly compatible with seizures arising from
the temporal lobe (lip smacking, ipsilateral motor automatism,
and contralateral dystonia) and confirms the diagnosis by finding
focal epileptiform discharges on electroencephalography and
cortical dysplasia in the left temporal lobe on brain imaging.
To prevent further seizures the specialist advises treatment with
antiepileptic drugs (AEDs). The patient is reluctant to start
treatment because she has read that AEDs have many adverse
effects, could interact with her oral contraception, and are
harmful for babies. She wonders if there are newer AEDs that
for her might be better than the traditional ones.
What are the newer antiepileptic drugs?
Epilepsy is resistant to drug treatment in a third of patients.1
Driven by this high prevalence of drug resistance, 12 agents
have been developed to treat adult epilepsy since the late 1980s.
These are often referred to collectively as the “newer”
antiepileptic drugs—that is, newer than the established drugs,
such as phenobarbital, phenytoin, carbamazepine, sodium
valproate, and several benzodiazepines, with phenobarbital
having been around for 100 years.2 In this article we will review
the clinical use of (in chronological order of approval in the
United Kingdom) lamotrigine, gabapentin, topiramate,
oxcarbazepine, levetiracetam, pregabalin, zonisamide, and
lacosamide (table 1⇓). We will not discuss the other newer
AEDs tiagabine and vigabatrin because they are rarely used for
focal epilepsy in adults (owing to efficacy and safety concerns
respectively) or eslicarbazepine acetate and retigabine, which
have only recently been approved and for which clinical
experience is therefore limited.
Howwell do the newer antiepileptic drugs
work?
Add-on therapy
To obtain licensing approval as add-on therapy, all AEDs have
to show superior efficacy compared with placebo in double
blind randomised controlled trials. In regulatory studies for
AEDs, the primary efficacy measure is statistical significance
against placebo for responder rate in Europe (defined as a ≥50%
reduction in seizure frequency) and median reduction in seizure
frequency in the United States.4 A recent meta-analysis that
evaluated the clinical effectiveness and tolerability of the newer
AEDs included 62 placebo controlled studies in children and
adults in terms of responder and withdrawal rates (table 2⇓).5
Owing to methodological heterogeneity—such as in the range
of dosages tested and of treatment durations (8-26 weeks)—and
the small differences found, caution is needed in drawing
comparisons between these drugs. In addition, the clinical
relevance of the responder rate as a useful clinical end point
remains questionable. The recent consensus from the
International League Against Epilepsy6 proposes that a
treatment’s success should be defined by sustained freedom
from seizures, as that is the only efficacy outcome consistently
associated with improved quality of life (and in the UK the only
efficacy outcome that allows a patient to drive legally). Using
this measure, another meta-analysis showed that the overall
weighted pooled-risk difference in favour of the newer AEDs
compared with placebo for freedom from seizures during the
limited study periods was only 6% (95% confidence interval
4% to 8%; number needed to treat in terms of freedom from
seizures, 16).7
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Monotherapy
Several of the newer AEDs have shown efficacy similar to that
of the older drugs (mostly carbamazepine), and sometimes
similar to that of each other, for the treatment of new onset focal
epilepsy in adults in head to head monotherapy trials and have
been approved for this indication in the UK and other European
countries.8 These approved drugs include levetiracetam,
lamotrigine, oxcarbazepine, and topiramate and in some
countries gabapentin. Seizure-free rates for a year in this highly
selective population have increased to about 60% as the design
of the studies has evolved.9
However, although there is evidence of efficacy under controlled
research conditions for these drugs, their clinical effectiveness
and cost effectiveness have been poorly studied. The greater
overall effectiveness for focal seizures (mostly in terms of better
tolerability) of lamotrigine compared with carbamazepine,
oxcarbazepine, and gabapentin in the randomised open-label
Standard and NewAntiepileptic Drugs (SANAD) study of 1721
patients arguably makes it the drug of first choice in this clinical
setting.10 The SANAD study found that gabapentin had
significantly inferior efficacy compared with carbamazepine,
and most experts do not recommend gabapentin as initial
monotherapy.
How safe are the newer antiepileptic
drugs?
All AEDs are associated with a range of adverse effects, the
main reason for withdrawal in regulatory trials.5 Many adverse
effects were detected only during postmarketing surveillance,
and their long term adverse effects (such as on bone health) are
unknown.
Idiosyncratic reactions
Such reactions are unpredictable adverse effects independent
of dosage.11 The most common of these is rash, which develops
in 3-5% of patients taking lamotrigine, zonisamide, or
oxcarbazepine but in <1% of those taking topiramate,
levetiracetam, gabapentin, or pregabalin.12 Lamotrigine and
oxcarbazepine can rarely lead to Stevens-Johnson syndrome or
toxic epidermal necrolysis. Other rare idiosyncratic reactions
include hepatitis, pancreatitis, and blood dyscrasias.
Ophthalmic effects
Rare cases of acute angle-closure glaucoma and myopia have
been reported with topiramate.
Neurotoxicity
Typical dose related symptoms including nausea, diplopia,
dizziness, headache, tiredness, somnolence, sedation, and ataxia
can occur with all AEDs.13
Renal calculi
Topiramate and zonisamide carry a small (1%) risk of
symptomatic renal calculi as both drugs inhibit carbonic
anhydrase.
Cardiac effects
Minor prolongation in the PR interval has been observed in
clinical studies with lacosamide.
Psychiatric effects
Topiramate is associated with anorexia, weight loss, word
finding difficulties, and neuropsychiatric complications.
Behavioural problems, such as agitation, aggression, hostility,
psychosis, anxiety, and depression, have been reported in
patients treated with levetiracetam. Zonisamide can also produce
or exacerbate psychiatric comorbidities, particularly depression.14
The US Food and Drug Administration analysed data from 199
placebo controlled trials of 11 AEDs and found an increase in
risk of suicidal behaviour or ideation among patients receiving
them (0.43%) compared with those receiving placebo (0.22%).15
A community based case-control study in treated epilepsy
documented increased risk of suicidal behaviour associated with
some newer AEDs (such as topiramate, levetiracetam) only in
patients with a high risk of depression.16
Teratogenicity
Recent data from EURAP, the largest international prospective
cohort study of 3909 pregnancies, reported that in utero exposure
to lamotrigine monotherapy was associated with an overall,
dose dependent rate of major fetal malformation at 1 year of
age that ranged from 2% (<300mg/day) to 4.5% (≥300mg/day).
This was less than that with carbamazepine (3.4% to 8.7%),
phenobarbital, (5.4% to 13.7%) and particularly sodium
valproate (5.6% to 24.2%).17TheUKpregnancy register reported
a rate of major fetal malformation for untreated women with
epilepsy (n=239) of 3.5% (95% confidence interval 1.8% to
6.8%).18 Children exposed to lamotrigine in utero had similar
IQs at age 3 years to those exposed to phenytoin and
carbamazepine, which was around 10 percentage points higher
than those taking high dose sodium valproate.19 Data from the
US and UK pregnancy registries indicate an increased risk of
oral clefts in infants exposed to topiramate monotherapy during
the first trimester.20 Sufficient data for other newer AEDs are
lacking, although preliminary experience from the UK
pregnancy registry has suggested a low risk of teratogenicity
with levetiracetam.21
What are the precautions?
Precautions relate to potential adverse effects as discussed
above. Examples are outlined as follows.
Rash
Closely monitor patients with a history of allergic rash when
introducing an AED as they have an approximate fivefold
increased risk of developing another rash.12Avoid oxcarbazepine
in patients with a history of rash induced by carbamazepine
because of a cross sensitivity rate between these drugs of
25-31%.
Cardiac problems
For patients with a history of cardiac problems, including
conduction block, taking drugs known to prolong the PR
interval, and for those aged over 65, use lacosamide cautiously
and perform electrocardiography before starting treatment and
after titration to optimal dosage.
History of psychiatric illness
Avoid topiramate, levetiracetam, and zonisamide, or, if essential,
use these cautiously.
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History of renal calculi
Avoid topiramate and zonisamide as they inhibit carbonic
anhydrase; advise all patients taking these drugs to avoid
dehydration.
Renal impairment
For patients with renal impairment prescribe lower doses of
gabapentin, levetiracetam, and pregabalin as these are
predominantly excreted unchanged in the urine.
Interaction with oral contraceptives
As oxcarbazepine and topiramate (at daily doses above 200mg)
selectively induce the breakdown of the oestrogenic component
of oral contraception,13 patients taking oral contraception need
formulations with higher doses (50 μg) of oestrogen, with
subsequent adjustment of hormones depending on any
breakthrough bleeding; other contraceptive measures must be
taken until the menstrual pattern has been stable for at least
three months. As the oestrogenic component of oral
contraception significantly increases the metabolism of
lamotrigine, the dosage of lamotrigine may need adjustment
when starting combined oral contraception (to maintain seizure
control) and when stopping the pill (to minimise adverse effects
of lamotrigine).22
Pregnancy
Limited data are available on the teratogenic risk of the newer
AEDs. Counsel women of childbearing potential on pregnancy
matters early.23 Advise them to plan pregnancy, so that any
changes to their regimen of AED treatment can be made before
conception (because teratogenesis may occur early in the first
trimester). Treatment with AEDs should be continued during
pregnancy on the basis that seizures, especially convulsive
seizures, are more harmful to the mother and fetus than are the
drugs themselves; however, treatment should be tapered to a
minimal effective dose before pregnancy, if possible to a single
AED. Supplemental folic acid is advised (≥400 μg daily) before
conception and during pregnancy to reduce the risk of major
congenital malformation.24 Offer prenatal diagnosis using
targeted fetal ultrasonography to detect any major structural
abnormalities. After delivery, encourage all mothers to breast
feed their babies. If the AED dose, particularly that of
lamotrigine, has been increased during pregnancy, consider a
reduction in dosage after delivery.
Breast feeding
Lamotrigine can accumulate in the breastfed baby because of
slow elimination. However, few data relate to the other newer
AEDs. As a general rule, if the baby is noted to be drowsy or
sedated, breast feeding should be alternated with bottle feeding
or discontinued.
How are the newer antiepileptic drugs
taken and monitored?
All the newer AEDs discussed in this article are taken orally.
Oxcarbazepine and levetiracetam are available in liquid
formulations. Lacosamide is also available as a syrup and by
intravenous injection. An intravenous formulation of
levetiracetam has been licensed in Europe for patients aged ≥4
years when oral administration is temporarily not feasible.
In general, start newer AEDs at low dosage, with increments
over several weeks to establish an effective and tolerable
regimen.13 Some agents, such as gabapentin and levetiracetam,
can be started at effective doses with or without rapid titration,
whereas others, such as lamotrigine and topiramate, require
slow titration to reduce the risk of rash and cognitive
impairment, respectively. Slow titration will also facilitate the
development of tolerance to sedation and will ensure early
detection of potentially serious idiosyncratic reactions.
Once the target dosage has been reached, adjust the dose further
on the basis of seizure control and tolerability. Routine
measurement of serum concentrations of the newer AEDs is not
recommended (and not available in most clinical settings), as
they do not correlate well with efficacy or side effects.25
However, serum concentrations of lamotrigine fall dramatically
during pregnancy, in patients who have recently started taking
an oral contraceptive containing oestrogen, and in women just
before the onset of the menses. Lamotrigine monitoring is
particularly helpful in guiding dosing during pregnancy.24 Such
monitoring is not available routinely across the UK and is best
performed with advice from an epilepsy specialist. Arguably,
however, lamotrigine concentrations should be measured before
conception, regularly throughout pregnancy, and in the
puerperium.25
How cost effective are the newer
antiepileptic drugs?
Whether the better tolerability and interaction profile of newer
AEDs are worth the higher price has been much debated. High
quality cost effectiveness studies are lacking. The guidelines
from the National Institute for Health and Clinical Excellence
(NICE) included cost utility analyses of AEDs and found
lamotrigine to be the most cost effective monotherapy (although
carbamazepine may be as cost effective).26 However, such cost
utility analyses often do not adequately account for indirect or
“hidden” costs such as interactions between drugs and long term
adverse effects. Moreover, generic formulations are becoming
available for many of the newer AEDs, thus driving down
prescription costs.
How do the newer antiepileptic drugs
compare with the established ones?
Given the limited number of comparative studies, AED
treatment for the individual patient is not based entirely on these
and depends also on the patient’s age, weight, sex,
comorbidities, and perceived differences in adverse effects,
propensity for interactions, and cost. Owing to the absence of
adequate evidence, judgments about treatment choice (in an
attempt to be rational) are based on what we think we know
about these other factors. Table 3⇓ lists some advantages and
disadvantages of the established and newer AEDs.
Choice of drug in newly diagnosed epilepsy
Based on a systematic review and consideration of clinical
benefits, harms, and cost effectiveness, the updated NICE
guidelines recommend offering carbamazepine or lamotrigine
as first line treatment to children, young people, and adults with
newly diagnosed focal seizures; if these are unsuitable or not
tolerated, NICE recommends levetiracetam (if its acquisition
cost falls to at least 50% of the value at June 2011),
oxcarbazepine, or sodium valproate.26 The American Academy
of Neurology supports starting treatment with the older AEDs
and lamotrigine, gabapentin, oxcarbazepine, or topiramate.
Choice will depend on individual patients’ characteristics.27 The
International League against Epilepsy adopts a stricter
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classification of evidence, supporting only carbamazepine,
phenytoin, and valproic acid as initial monotherapy for partial
onset seizures in adults and lamotrigine and gabapentin for older
people.28 On the basis of the double blind, randomised
monotherapy study of levetiracetam versus extended release
carbamazepine in newly diagnosed epilepsy, which fulfilled the
strict criteria of the International League against Epilepsy,
levetiracetam can also be recommended for this indication.9
These differing recommendations may reflect fundamental
differences in the purposes of the various guidelines and in the
approaches adopted by the groups developing them.
Choice of drug in uncontrolled epilepsy
As very few head to head comparisons of new AEDs exist for
the treatment of drug resistant epilepsy, choice remains largely
empirical. The increasing number of available agents has
encouraged consideration of their different mechanisms of action
(table 1⇓) in optimising their efficacy in combination. The broad
spectrum AEDs levetiracetam, topiramate, and zonisamide,
which have multiple mechanisms of action, are often chosen in
drug resistant epilepsy.29
Our case scenario
Treatment with AEDs is indicated for our patient with recurrent
focal seizures, the latest of which seem to have developed into
a secondarily generalised seizure (epileptic seizure with focal
onset and subsequent bilateral convulsion). On the basis of this
review and in line with NICE guidance, given the patient’s
childbearing potential, the drug of choice would be lamotrigine,
preferably maintained at <300 mg/day. Ideally, monitor the
concentration before conception, during pregnancy, and in the
puerperium. We do not recommend carbamazepine for her
because of its comparatively higher risk of fetal malformation
(when the dose is ≥400 mg/day) and enzyme induction of the
oestrogenic component of her oral contraception. Levetiracetam
can also be considered because it is effective as controlled
release carbamazepine and preliminary data suggest a low risk
of teratogenicity, although NICE asserts that it is not as cost
effective as lamotrigine at June 2011 unit costs.
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Tips for patients
• Drug treatment aims at preventing the development and spread of seizures (the electrical consequence of an underlying process in
the brain) but does not affect the underlying cause of the epilepsy
• Keep a diary of any seizures and side effects you have experienced and discuss the record with your general practitioner or epilepsy
specialist during consultations
• Discuss the common problems associated with your treatment with your general practitioner before starting any new drug
• If you think you are experiencing a side effect with your epilepsy treatment, discuss this as soon as possible with your general
practitioner or epilepsy specialist
• If you are a woman you should seek advice on contraception to ensure that the epilepsy treatment does not interfere with your oral
contraception and request referral to an epilepsy specialist if you are planning a pregnancy
• Health problems that arise months or years after taking an unchanged treatment schedule are unlikely to be the result of the antiepileptic
drugs but should be discussed with your doctor as they may affect your epilepsy treatment
• Adding another medicine can sometimes interfere with the epilepsy drugs, producing side effects or reducing the efficacy of these
drugs and thus worsening seizure control. Check this specifically with your doctor when he or she recommends starting you on any
new drug
• Very rarely an epileptic seizure can affect the function of the heart, lungs, or brain, resulting in sudden death, and so taking the
antiepileptic drugs is essential
Tips for general practitioners
• Refer patients with suspected epilepsy to a specialist in epilepsy care for diagnosis, investigation, and treatment
• If problems arise, seek advice from the appropriate neurologist or local epilepsy specialist nurse
• Refer patients planning a pregnancy to an epilepsy specialist for advice, optimisation of the antiepileptic drug regimen, and initiation
of folic acid
• When introducing adjunctive treatment in a patient with drug resistant epilepsy it may be necessary to reduce the dose of one of the
other drugs, particularly if this is being taken at a high dose, to facilitate optimal tolerability
• If a clinical problem occurs after an antiepileptic drug monotherapy or multidrug regimen has been stable for some years, the problem
is unlikely to be caused by the antiepileptic drugs
• Routine therapeutic drug monitoring of antiepileptic drugs is not necessary. Use monitoring only to ask a clinical question, such as
whether the patient is complying with the treatment
• If a patient is considering stopping treatment, advise him or her to discuss the risks with an epilepsy specialist before finalising the
decision
Tables
Table 1| Mechanisms of action, year first licensed, and approved indications for newer antiepileptic drugs discussed in this review for use
in adults in the United Kingdom
Indications
Mechanism of action
Antiepileptic drug (year first
licensed) MonotherapyAdd-on therapySeizure type*
YesYesFocal, generalisedBlocks fast-inactivated state of sodium
channel
Lamotrigine (1991)
YesYesFocalBlocks fast-inactivated state of sodium
channel
Oxcarbazepine (2000)
YesFocalBlocks slow-inactivated state of sodium
channel
Lacosamide (2008)
YesFocalBlocks high voltage-activated calcium
channel
Gabapentin (1993)
YesFocalBlocks high voltage-activated calcium
channel
Pregabalin (2004)
YesYesFocal, generalisedModulates synaptic vesicle protein 2ALevetiracetam (2000)
YesYesFocal, generalisedVarious actions on multiple targetsTopiramate (1995)
YesFocalVarious actions on multiple targetsZonisamide (2005)
*Seizures are broadly classified into focal or generalised on the basis of the mode of onset.3 Focal (partial) epileptic seizures are conceptualised as originating
within networks limited to one hemisphere and may be discretely localised or more widely distributed. Focal seizures may or may not lead to impairment of
consciousness or awareness and may evolve to bilateral convulsive seizures (secondarily generalised tonic-clonic seizure). Generalised epileptic seizures are
conceptualised as originating at some point within, and rapidly engaging, bilaterally distributed networks. Examples include (primarily) generalised tonic-clonic,
absence, myoclonic seizures.
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Table 2| Meta-analysis of responder rate and withdrawal rate for newer antiepileptic drugs as add-on therapy for uncontrolled focal epilepsy
in randomised controlled trials (modified from Costa et al, 20115)
ZonisamideTopiramatePregabalinOxcarbazepineLamotrigineLevetiracetamLacosamideGabapentin
Data for responder rate*
4/85010/13126/18672/96112/131410/16933/10926/1187Trials/patients (n/n)
32.6/13.144.8/15.237.2/15.239.5/16.628.3/15.140.1/17.037.7/22.619.9/10.9Responder rates for
drug/placebo (%)
2.99 (2.07 to
4.32)
4.31 (3.07 to
6.06)
3.61 (2.21 to
5.89)
3.30 (1.80 to
6.08)
2.34 (1.66 to
3.30)
3.75 (2.71 to
5.20)
2.06 (1.54 to
2.76)
2.08 (1.47 to
2.96)
Odds ratio (95% CI)
12 (10-16)9 (8-10)10 (8-13)9 (7-15)12 (10-18)8 (8-10)10 (8-15)19 (14-31)Number needed to
treat
Data for withdrawal rate†
4/85010/13126.18672/96113/176710/17213/11056/1206Trials/patients (n/n)
20.6/12.916.5/6.923.2/17.141.1/19.916.5/14.111.7/11.621.2/12.98.8/10.0Withdrawal rates for
drug/placebo (%)
1.59 (1.08 to
2.34)
2.38 (1.54 to
3.65)
1.52 (1.17 to
1.98)
2.27 (1.62 to
3.17)
1.19 (0.90 to
1.57)
0.97 (0.69 to
1.36)
1.8 (1.26 to
2.56)
0.99 (0.66 to
1.5)
Odds ratio (95% CI)
23 (9-119)26 (20-43)19 (13-47)10 (8-15)NANA19 (13-42)NANumber needed to
harm
CI=confidence interval; NA=not applicable.
*Responders had at least a 50% reduction in seizure frequency.
†Withdrawals were mostly because of adverse events.
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Table 3| Advantages and disadvantages of the established and newer antiepileptic drugs
DisadvantagesAdvantages
Older antiepileptic drugs
Dizziness, headache, drowsiness, diplopia, rash, hyponatraemia, osteoporosis,
enzyme induction, blood dyscrasias
Cost effective for new onset focal seizuresCarbamazepine
Sedation, behavioural disturbances, hyperactivity, rash, teratogenesis, osteoporosis,
folate deficiency, enzyme induction, Dupuytren’s contracture
Broad spectrum of activity; once daily; cheapPhenobarbital
Headache, dizziness, ataxia, rash, gum hyperplasia, hirsutism, acne, osteoporosis,
peripheral neuropathy, enzyme induction, saturation kinetics, cerebellar atrophy
Once daily; rapid titration; intravenous formulation available;
cheap
Phenytoin
Nausea, diarrhoea, lethargy, drowsiness, weight gain, thrombocytopenia, alopecia,
tremor, extrapyramidal symptoms, enzyme inhibition, teratogenesis
Cost effective for new onset generalised seizures; broad
spectrum of activity; rapid titration; few interactions
Sodium valproate
Newer antiepileptic drugs
Drowsiness, dizziness, ataxia, weight gain, diarrhoea, dose adjustment needed in
renal impairment
Low risk of allergic reactions; low risk of drug interactionGabapentin
Dizziness, headache, diplopia, nausea, vomiting, tremor, rash, minor prolongation
in the PR interval
Low risk of drug interaction; intravenous formulation availableLacosamide
Headache, insomnia, diplopia, dizziness, ataxia, rash, interacts with combined
contraception pill
Cost effective for new onset focal seizures; broad spectrum;
few interactions; better tolerated than older drugs; low risk
of teratogenicity
Lamotrigine
Somnolence, headache, neuropsychiatric and behavioural effects such as
aggression, depression, dose adjustment needed in renal impairment
Broad spectrum of activity; intravenous formulation available;
low risk of drug interaction
Levetiracetam
Dizziness, nausea, vomiting, headache, drowsiness, rash, hyponatraemia, interacts
with combined contraception pill
Better tolerated than older drugsOxcarbazepine
Dizziness, somnolence, headache, ataxia, weight gain, peripheral oedema, sexual
dysfunction, dose adjustment needed in renal impairment
Low risk of allergic reactions; low risk of drug interactionPregabalin
Dizziness, paraesthesia, somnolence, confusion, fatigue, weight loss, renal stones,
neuropsychiatric effects, interacts with combined contraception pill
Broad spectrum; weight loss in obesityTopiramate
Anorexia, dizziness, fatigue, nausea, vomiting, weight loss, renal stones, rash,
neuropsychiatric effects especially depression
Broad spectrum; once daily; weight loss in obesity; low risk
of drug interaction
Zonisamide
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